公开(公告)号：US20230414718A1

公开(公告)日：2023-12-28

申请号：US18253651

申请日：2021-11-18

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro KOSAI ,  Eriko MATSUDA

IPC: A61K38/18 ,  C12N15/86 ,  C07K14/475 ,  A61P3/10 ,  A61P1/18

CPC classification number: A61K38/1833 ,  C12N15/86 ,  C07K14/4753 ,  A61P3/10 ,  A61P1/18

Abstract: An agent for protecting and/or regenerating pancreatic β cells in a mammal with diabetes, containing a recombinant viral vector expressing a hepatocyte growth factor (HGF), wherein the agent is administered at a dose of 1010-1012 virus particles (vp)/kg body weight, and the viral vector contains a nucleic acid encoding HGF downstream of a promoter with transcriptional activity capable of affording a therapeutically effective blood HGF level at said dose is provided by the present invention.

公开(公告)号：US20240173381A1

公开(公告)日：2024-05-30

申请号：US18548807

申请日：2022-03-02

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro KOSAI ,  Eriko MATSUDA

IPC: A61K38/18 ,  A61K48/00 ,  A61P3/10 ,  C12N15/86

CPC classification number: A61K38/1808 ,  A61K38/1833 ,  A61K48/0033 ,  A61P3/10 ,  C12N15/86 ,  C12N2750/14143

Abstract: The present invention provides a novel therapeutic means that is relatively low invasive and capable of exerting a desired therapeutic effect on diabetes including T1D. Specifically, an agent for protecting and/or regenerating a pancreatic β cell in a mammal with diabetes is provided, which contains a nucleic acid encoding a heparin-binding epidermal growth factor-like growth factor (HB-EGF), wherein the agent is systemically administered. The aforementioned preparation in combination with a nucleic acid encoding hepatocyte growth factor (HGF) is also provided.